A leading psychiatrist has hailed ‘a major breakthrough’ in the treatment of attention-deficit hyperactivity disorder (ADHD) – after a drug was able to ease symptoms of the condition without the risks of standard medications.
Dr Michael Halassa, professor of psychiatry at Virginia Tech’s Fralin Biomedical Research Institute, said the medication, which showed promising results in early trials this week, could be as revolutionary for ADHD as Ozempic has been for obesity.
‘If the medication can address ADHD symptoms without the risks of existing drugs it would be a true game-changer,’ he added. ‘It’s a very exciting finding.’
The medication – known as ALKS 7290 – works
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.